ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2966

Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index?

Ali Ugur Unal1, Hale Gulcin Yildirim2, Ceylan Cikikci2, Gulsen Ozen3, Nevsun Inanc3, Pamir Atagunduz3, Tulin Ergun4 and Haner Direskeneli5, 1Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 2Marmara University Faculty of Medicine, Istanbul, Turkey, 3Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, 4Marmara University, School of Medicine, Dermatology, Istanbul, Turkey, 5Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey

Meeting: ACR/ARHP Annual Meeting 2016

Date of first publication: September 28, 2016

Keywords: Behcet's syndrome

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Vasculitis - Poster III: Rarer Vasculitides

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Behcet’s Disease (BD) is a systemic vasculitis characterized by involvement of vessels of any size and type. In the course systemic vasculitis, it is important to distinguish disease activity from damage to prevent unnecessary immunosuppression. Damage is also an important surrogate for long-term outcome in vasculitis. Although a well-established validated damage index, “vasculitis damage index” (VDI) is available for vasculitis, its performance in BD has never been assessed.  In this study we assessed the damage in BD by using VDI, to determine whether VDI covers all BD-associated damage and lastly to develop a preliminary BD-specific damage index with the obtained data.

Methods: A total of 139 consecutive patients with BD (F/M: 58/81, mean age 38.9±10.9 yrs, disease duration 9.5±7.4 yrs)  from a single center were evaluated for damage in a cross-sectional study using the VDI. Considering the patients data and items of VDI with further literature search for BD-specific damages, new items (detailed cardiovascular, ocular, and vascular involvement-, particularly venous disease-related damages) were added to VDI. This modified VDI (Behcet’s Disease-VDI [B-VDI]) was also scored in allpatients.

Results: Seventy seven patients (55.4%) had major organ involvement and 105 (75.5%) patients were on immunosupressive (IS) treatment (Table 1). The mean VDI score was 0.3±0.7 and majority of the patients had score “0” (“0” in 107 [77%], “1” in 22 [15.8%], “2” in 7 [5%], “3” in 1 [0.7%], and “4” in 2 [1.4%] patients).  The mean B-VDI score was 0.6±1.1 (“0” in 92 [66.2%], “1” in 25 [18%], “2” in 13 [9.4%], “3” in 4 [2.9%] and “4” in 3 [2.2%] patients, “5” in 1 [0.7%], and “6” in 1 [0.7%] patient) and was significantly higher than VDI (p<0.001). The main difference between VDI and B-VDI was in vascular (0.05±0.2 vs 0.3±0.6, p<0.001) damage items. Both VDI and B-VDI scores were significantly higher in patients with major organ involvement compared to mucocutaneous BD. Both scores were also positively correlated with the age, disease duration and total duration of IS treatment. When individual organ items evaluated, it was observed that damage in patients with major organ involvement was predominantly associated with ocular and vascular involvements. Although VDI-eye and B-VDI-eye scores were not significantly different (both 0.3±0.6, p=0.32), B-VDI-vascular scores were significantly higher than VDI-vascular scores both in the entire cohort and in patients with major organ involvement (0.6±0.8 vs 0.1±0.3, p<0.001).

Conclusion: Both VDI and B-VDI capture reliable data on damage among patients with BD. However, VDI does not cover all vascular involvement-related damages of BD. Addition of new items, especially about vascular damage, to VDI will provide more comprehensive damage assessment in BD. Further prospective followup is required to determine the prognostic value of these damage indices in BD.    


Disclosure: A. U. Unal, None; H. G. Yildirim, None; C. Cikikci, None; G. Ozen, None; N. Inanc, None; P. Atagunduz, None; T. Ergun, None; H. Direskeneli, None.

To cite this abstract in AMA style:

Unal AU, Yildirim HG, Cikikci C, Ozen G, Inanc N, Atagunduz P, Ergun T, Direskeneli H. Assessment of Damage in Behcet’s Disease: Do We Need a Specific Damage Index? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/assessment-of-damage-in-behcets-disease-do-we-need-a-specific-damage-index/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2016

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-damage-in-behcets-disease-do-we-need-a-specific-damage-index/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology